Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma

Cancer

Volumn 110, Issue 11, 2007, Pages 2576-2586

  Hodgson, David C ^a   Koh, Eng Siew ^a   Tu, Huan Tran ^a   Heydarian, Mostafa ^b   Tsang, Richard ^a   Pintilie, Melania ^a   Xu, Tony ^c   Huang, Lei ^c   Sachs, Rainer K ^c   Brenner, David J ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

Biological modeling; Extended field; Hodgkin lymphoma; Individualized second cancer risk; Involved field; Mantle; Mathematical modeling; Radiation dose; Radiotherapy

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HODGKIN DISEASE; HUMAN; LUNG CANCER; MALE; PRIORITY JOURNAL; RADIATION DOSE;

BREAST NEOPLASMS; FEMALE; HODGKIN DISEASE; HUMANS; INCIDENCE; LUNG NEOPLASMS; LYMPHATIC IRRADIATION; MALE; MEDIASTINAL NEOPLASMS; MODELS, STATISTICAL; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY DOSAGE; RISK;

EID: 36448997706     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23081     Document Type: Article

References (41)

1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3449.
2. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106:3358-3365.
3. Gilbert E, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003;159:161-173.
4. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137:129-131.
5. Comment in: Ann Intern Med. 2003;138:356-357; author reply, 357. Summary for patients in: Ann Intern Med. 2002;137:I38.
6. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498-509.
7. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-4394.
8. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494.
9. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among five-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489-1497.
10. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12:312-325.
11. Engert A, Pluetschow A, Eich HT, Diehl V. Combined modality treatment of two or four cycles of ABVD followed by involved field radiotherapy in the treatment of patients with early stage Hodgkin's lymphoma: update interim analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). Blood. 2005;106:2673.
12. Eghbali E, Brice P, Cremmers GY, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F Trial. Blood. 2005;106:814.
13. Barton MB, Rose A, Lonergan D, Thornton D, O'Brien P, Trotter G. Mantle planning: report of the Australasian Radiation Oncology Lymphoma Group film survey and consensus guidelines. Australas Radiol. 2000;44:433-438.
14. Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13.
15. Zellmer DL, Wilson JF, Janjan NA. Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys. 1991;21:1343-1351.
16. Gray LH. A Symposium Considering Radiation Effects in the Cell and Possible Implications for Cancer Therapy: a Collection of Papers. Cellular Radiation Biology. Baltimore, Md: Williams & Wilkins; 1965:8-25.
17. Mole RH. Ionizing radiation as a carcinogen: practical questions and academic pursuits. The Silvanus Thompson Memorial Lecture delivered at The British Institute of Radiology on April 18, 1974. Br J Radiol. 1975;48:157-169.
18. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971-980.
19. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-475.
20. Travis LB, Gilbert E. Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use. Radiat Res. 2005;163:695-696.
21. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci U S A. 2005;102:13040-13045.
22. Little MP. A multi-compartment cell repopulation model allowing for inter-compartmental migration following radiation exposure, applied to leukaemia. J Theor Biol. 2007;245:83-97.
23. Shuryak I, Sachs RK, Hlatky L, Little MP, Hahnfeldt P, Brenner DJ. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. J Natl Cancer Inst. 2006;98:1794-1806.
24. Lindsay KA, Wheldon EG, Deehan C, Wheldon TE. Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy. Br J Radiol. 2001;74:529-536.
25. Sacher GA, Trucco E. Theory of radiation injury and recovery in self-renewing cell populations. Radiat Res. 1966;29:236-256.
26. Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:1195-1203.
27. Yahalom J. Radiation Field Design and Dose in Hodgkin's Disease and Non-Hodgkin's Lymphoma: New Concepts, New Tools [compact disc]. Educational Session 312. Educational Syllabus, 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta, GA, October 3-7, 2004.
28. U.S. National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results. SEER*-Stat [computer program]. Version 6.1.4. Bethesda, Md: National Cancer Institute; April 14, 2005. Available at: http://seer.cancer.gov/seerstat/
29. Lamarre L, Jacobson JO, Arsenberg AC, et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730-739.
30. Health, United States, 2006. Washington, DC: U. S. Department of Health and Human Services; 2006.
31. Lew E, Garfinkel L. Differences in mortality and longevity by sex, smoking status and health status. Transact Soc Actuaries. 1987;39:107-130.
32. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17:1749-1760.
33. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270-277.
34. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997;79:1203-1210.
35. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487-497.
36. Ng AK, Bernardo MV, Weiler E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100:1989-1996.
37. Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13:1786-1791.
38. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428-1437.
39. Smitt MC, Stouffer N, Owen JB, Hoppe RT, Hanks GE. Results of the 1988-1989 Patterns of Care Study process survey for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1999;43:335-339.
40. Hughes DB, Smith AR, Hoppe R, et al. Treatment planning for Hodgkin's disease: a patterns of care study. Int J Radiat Oncol Biol Phys. 1995;33:519-524.
41. M'Kacher R, Girinsky T, Koscielny S, et al. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys. 2003;57:321-326.